Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 1086
- Registration Number
- NCT00022516
- Locations
- 🇦🇺
Christchurch Hospital, Christchurch, Australia
🇧🇪CHU Liege - Domaine Universitaire du Sart Tilman, Liege, Belgium
🇮🇹Ospedale Sant' Eugenio, Rome, Italy
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
- Conditions
- Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesPrecancerous/Nonmalignant ConditionSmall Intestine Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT00006379
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Registration Number
- NCT00017108
- Locations
- 🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium
🇭🇺County Hospital, Kaposvar, Hungary
🇳🇱Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
- Conditions
- Kidney Cancer
- Interventions
- Biological: filgrastimBiological: therapeutic allogeneic lymphocytesDrug: cyclophosphamideDrug: fludarabine phosphateDrug: methotrexateDrug: tacrolimusProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT00027573
- Locations
- 🇺🇸
CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸CCOP - Oklahoma, Tulsa, Oklahoma, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
- Conditions
- Cancer
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: cisplatinDrug: cyclophosphamideDrug: etoposideDrug: ifosfamideDrug: mesnaDrug: paclitaxelProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT00002854
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Biological: filgrastimDrug: cisplatinDrug: doxorubicin hydrochlorideDrug: cyclophosphamideDrug: mesnaDrug: melphalanDrug: paclitaxelDrug: tamoxifen citrateProcedure: bone marrow ablation with stem cell supportProcedure: peripheral blood stem cell transplantationProcedure: conventional surgery
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT00003042
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Riverside Haematology Group
- Target Recruit Count
- 660
- Registration Number
- NCT00003603
- Locations
- 🇬🇧
Hammersmith Hospital, London, England, United Kingdom
Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- German Hodgkin's Lymphoma Study Group
- Target Recruit Count
- 220
- Registration Number
- NCT00025636
- Locations
- 🇧🇪
Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium
🇩🇪Universitaetsklinikum Essen, Essen, Germany
🇩🇪Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet, Greifswald, Germany
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: filgrastimBiological: rituximabDrug: carmustineDrug: cyclophosphamideDrug: cytarabineDrug: doxorubicin hydrochlorideDrug: etoposideDrug: leucovorin calciumDrug: methotrexateDrug: prednisoneDrug: vincristine sulfateProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 79
- Registration Number
- NCT00020943
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma
- Conditions
- LymphomaLeukemia
- Interventions
- Drug: fludarabine phosphateDrug: CyclophosphamideBiological: PBSCDrug: G-CSFBiological: Donor lymphocytes
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Cancer and Leukemia Group B
- Target Recruit Count
- 47
- Registration Number
- NCT00006252
- Locations
- 🇺🇸
UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States
🇺🇸Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees, Voorhees, New Jersey, United States
🇺🇸UCSF Comprehensive Cancer Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.